The CNS renaissance: Innovations are reshaping neurological therapies

Disease-modifying therapies validate the shift

Recent landmark approvals demonstrate the shift from symptomatic treatments to genuine disease-modification. Biogen’s Leqembi and Eli Lilly’s Kisunla are the first disease-modifying Alzheimer’s therapies in two decades, while Bristol Myers Squibb’s Cobenfy is the first new schizophrenia mechanism in 35 years. These approvals establish regulatory precedents and show that disease modification is achievable in previously intractable CNS conditions, creating pathways for next-generation therapies targeting neuroinflammation, tau pathology and synaptic dysfunction.

Big pharma’s strategic re-engagement

Major pharmaceutical companies are returning to neuroscience with over $50bn of M&A activity across the past couple of years, including Johnson & Johnson’s $14.6bn Intra-Cellular acquisition and Bristol Myers Squibb’s $14.0bn Karuna purchase. Novartis’s partnership with Arrowhead Pharmaceuticals exemplifies strategic licensing, with $200m upfront and $2.0bn in potential milestones for alpha-synuclein RNA therapy. This re-engagement reflects massive unmet need and an impending patent cliff threatening $200bn in annual sales through 2030.

Investment landscape transformation

CNS start-ups attracted venture capital of $1.7bn in 2024, an 80% y-o-y increase, making neuroscience the third-largest specialty in venture funding. Investment opportunities span dedicated neuroscience exchange-traded funds (ETFs), established pharmaceutical CNS franchises, mid-cap specialists and small-cap biotechnology platform companies. Key themes include blood-brain barrier technologies, AI-driven discovery, psychedelic therapeutics, cell and gene therapies and precision neuroinflammation approaches.

To read the full report, click the download button at the top of the page.